This is a table of type bigram and their frequencies. Use it to search & browse the list to learn more about your study carrel.
bigram | frequency |
---|---|
rights reserved | 83 |
cutaneous manifestations | 56 |
coronavirus disease | 44 |
skin lesions | 43 |
eur acad | 42 |
dermatol venereol | 41 |
acad dermatol | 41 |
cord uid | 39 |
doc id | 39 |
venereol doi | 39 |
acute respiratory | 32 |
novel coronavirus | 29 |
like lesions | 23 |
skin manifestations | 22 |
respiratory syndrome | 21 |
informed consent | 20 |
given written | 20 |
written informed | 20 |
syndrome coronavirus | 20 |
case details | 19 |
severe acute | 19 |
systemic symptoms | 18 |
drug reaction | 16 |
accepted article | 16 |
skin cancer | 14 |
case series | 13 |
skin rash | 13 |
autoimmune blistering | 13 |
first perspective | 13 |
respiratory distress | 13 |
intensive care | 13 |
severe covid | 12 |
viral infection | 12 |
immunosuppressive therapy | 12 |
reserved key | 11 |
atopic dermatitis | 11 |
protective equipment | 11 |
viral infections | 11 |
skin symptoms | 11 |
dihs dress | 10 |
vascular skin | 10 |
genital ulcers | 10 |
healthcare workers | 9 |
blistering diseases | 9 |
cytokine storm | 9 |
disease severity | 9 |
skin biopsy | 9 |
clinical features | 9 |
sexually transmitted | 8 |
personal protective | 8 |
patient presented | 8 |
reactive protein | 8 |
dress syndrome | 8 |
health care | 8 |
systematic review | 8 |
distress syndrome | 8 |
care unit | 8 |
face mask | 8 |
erythematous rash | 8 |
normal range | 8 |
led us | 8 |
contact dermatitis | 8 |
androgen receptor | 8 |
patients infected | 7 |
dry cough | 7 |
great interest | 7 |
patients treated | 7 |
immune response | 7 |
world health | 7 |
livedo reticularis | 7 |
associated skin | 7 |
barr virus | 7 |
close contact | 7 |
cancer patients | 7 |
pityriasis rosea | 7 |
nasopharyngeal swab | 7 |
febrile rash | 7 |
observational study | 7 |
face masks | 7 |
interstitial pneumonia | 7 |
public health | 7 |
erythema multiforme | 7 |
coronavirus pandemic | 7 |
psoriatic patients | 7 |
health organization | 7 |
cag repeat | 7 |
chilblain lesions | 6 |
infected patients | 6 |
even though | 6 |
transmitted infections | 6 |
viral pneumonia | 6 |
consensus study | 6 |
mg day | 6 |
march th | 6 |
clinical manifestations | 6 |
nationwide consensus | 6 |
lockdown period | 6 |
medical history | 6 |
inflammatory cytokines | 6 |
two patients | 6 |
related skin | 6 |
prospective nationwide | 6 |
inflammatory response | 6 |
one patient | 6 |
risk factors | 6 |
cutaneous manifestation | 6 |
first report | 6 |
immunosuppressive treatment | 6 |
french observational | 6 |
kawasaki disease | 6 |
one case | 6 |
positive patients | 6 |
coronavirus infection | 6 |
rapid prospective | 6 |
advanced skin | 5 |
lesions may | 5 |
tested positive | 5 |
different types | 5 |
pediatric age | 5 |
tumor necrosis | 5 |
disease prevention | 5 |
resulted negative | 5 |
general population | 5 |
patients requiring | 5 |
european centre | 5 |
herpesvirus reactivations | 5 |
medical provisions | 5 |
urticarial lesions | 5 |
clinical manifestation | 5 |
hospitalized covid | 5 |
pandemic coronavirus | 5 |
case report | 5 |
laboratory tests | 5 |
psoriatic patient | 5 |
bullous pemphigoid | 5 |
blood count | 5 |
necrosis factor | 5 |
confirmed covid | 5 |
health workers | 5 |
covid pandemic | 5 |
primary chilblains | 5 |
may also | 5 |
dear editor | 5 |
two cases | 5 |
pcr sars | 5 |
influence immunosuppressive | 5 |
diverse cutaneous | 5 |
skin manifestation | 5 |
symptoms syndrome | 5 |
patient developed | 5 |
vascular damage | 5 |
chronic inflammatory | 5 |
leukocytoclastic vasculitis | 5 |
average age | 5 |
acral lesions | 5 |
bilateral interstitial | 5 |
hypersensitivity syndrome | 5 |
cold exposure | 5 |
nasopharyngeal swabs | 5 |
retiform purpura | 5 |
emergency department | 5 |
hospitalized patients | 5 |
ear loop | 4 |
ischemic lesions | 4 |
distinctive skin | 4 |
italian national | 4 |
induced hypersensitivity | 4 |
myocardial infarction | 4 |
pandemic condition | 4 |
adverse reactions | 4 |
adverse drug | 4 |
severe disease | 4 |
differential diagnosis | 4 |
exanthematous pustulosis | 4 |
acral necrosis | 4 |
disease caused | 4 |
skin conditions | 4 |
aibd patients | 4 |
skin diseases | 4 |
icu admissions | 4 |
acute genital | 4 |
social media | 4 |
virus infection | 4 |
surface area | 4 |
blistering disease | 4 |
medium size | 4 |
may lead | 4 |
herpes simplex | 4 |
size dermatological | 4 |
generalized exanthematous | 4 |
viral exanthem | 4 |
days later | 4 |
rash associated | 4 |
psoriatic arthritis | 4 |
prospective study | 4 |
ii level | 4 |
late onset | 4 |
body surface | 4 |
global coronavirus | 4 |
mucous membrane | 4 |
bullous hemorrhagic | 4 |
italian medium | 4 |
sudden onset | 4 |
emergency service | 4 |
dermatological clinic | 4 |
pandemic date | 4 |
ar cag | 4 |
mycophenolate mofetil | 4 |
clinical symptoms | 4 |
loop face | 4 |
infectious diseases | 4 |
coronavirus pneumonia | 4 |
cutaneous involvement | 4 |
critical covid | 4 |
covid patients | 4 |
social distancing | 4 |
global health | 4 |
clinical characteristics | 4 |
immunosuppressive drugs | 4 |
laboratory findings | 4 |
biological drugs | 4 |
first case | 4 |
bullous diseases | 4 |
three cases | 4 |
mycoplasma pneumoniae | 4 |
patient affected | 4 |
immunosuppressive therapies | 4 |
autoimmune bullous | 4 |
sars coronavirus | 4 |
ar gene | 4 |
negative results | 4 |
predisposed subjects | 4 |
case reports | 4 |
suspected covid | 4 |
dermatitis due | 4 |
level hospital | 4 |
oncological risk | 4 |
serological tests | 4 |
higher risk | 4 |
respiratory symptoms | 4 |
old man | 4 |
acute generalized | 4 |
urticarial eruption | 4 |
infection among | 4 |
patients affected | 4 |
severe cutaneous | 3 |
perivascular dermatitis | 3 |
clinical course | 3 |
patients day | 3 |
incubation period | 3 |
old female | 3 |
cutaneous adverse | 3 |
erythema nodosum | 3 |
membrane pemphigoid | 3 |
five cases | 3 |
developed covid | 3 |
dermatological manifestations | 3 |
acute urticaria | 3 |
dermatological consultations | 3 |
front line | 3 |
higher levels | 3 |
workers managing | 3 |
clinical diagnosis | 3 |
skin reactions | 3 |
similar cases | 3 |
coagulation characteristics | 3 |
european task | 3 |
growth rate | 3 |
skin damage | 3 |
multidisciplinary approach | 3 |
platelet count | 3 |
cohort study | 3 |
severely affected | 3 |
clinical presentation | 3 |
article key | 3 |
preliminary study | 3 |
mycoplasma pneumonia | 3 |
may include | 3 |
findings support | 3 |
common manifestations | 3 |
mask area | 3 |
exanthematic rashes | 3 |
prime minister | 3 |
di altobrando | 3 |
patient treated | 3 |
first described | 3 |
following days | 3 |
recent report | 3 |
interface dermatitis | 3 |
unknown infectious | 3 |
syndrome drug | 3 |
severe complications | 3 |
worse prognosis | 3 |
microvascular injury | 3 |
global public | 3 |
underlying pathology | 3 |
superficial perivascular | 3 |
present case | 3 |
cutaneous melanoma | 3 |
clinical enigma | 3 |
disease patients | 3 |
human herpes | 3 |
initial sample | 3 |
completely asymptomatic | 3 |
severe cases | 3 |
endothelial cells | 3 |
diagnostic delay | 3 |
cov infection | 3 |
submitted form | 3 |
much information | 3 |
lockdown measures | 3 |
viral exanthemata | 3 |
severe pneumonia | 3 |
dermatologic manifestation | 3 |
targetoid lesions | 3 |
patients undergoing | 3 |
infectious trigger | 3 |
important role | 3 |
patients suffering | 3 |
dermatologic care | 3 |
delay group | 3 |
including covid | 3 |
chest ct | 3 |
androgen sensitivity | 3 |
health service | 3 |
new contribution | 3 |
biological significance | 3 |
androgen response | 3 |
like vesicles | 3 |
family members | 3 |
scheduled visits | 3 |
cutaneous lesions | 3 |
symptomatic covid | 3 |
better quantify | 3 |
skin eruption | 3 |
inflammatory diseases | 3 |
verify whether | 3 |
mild disease | 3 |
polyglutamine repeat | 3 |
herpes virus | 3 |
oral aphtha | 3 |
skin rashes | 3 |
lymphocyte transformation | 3 |
skin disease | 3 |
trigger may | 3 |
inflammatory skin | 3 |
polymerase chain | 3 |
case rep | 3 |
transient livedo | 3 |
last days | 3 |
prevention measures | 3 |
skin lesion | 3 |
patient started | 3 |
surgical clothing | 3 |
androgenetic alopecia | 3 |
hand washing | 3 |
flexural exanthema | 3 |
current pandemic | 3 |
blood cell | 3 |
mg daily | 3 |
potential impact | 3 |
may help | 3 |
pulmonary disease | 3 |
acral cutaneous | 3 |
pediatric population | 3 |
clinical trial | 3 |
health emergency | 3 |
septic shock | 3 |
task force | 3 |
early phase | 3 |
trachomatis infections | 3 |
new coronavirus | 3 |
biopsy specimens | 3 |
chain reaction | 3 |
acute acro | 3 |
ministerial decree | 3 |
purpuric lesions | 3 |
increased risk | 3 |
like exanthem | 3 |
survival rates | 3 |
also possible | 3 |
spread worldwide | 3 |
heart failure | 3 |
physical examination | 3 |
young adults | 3 |
complement associated | 3 |
drug reactions | 3 |
new behaviors | 3 |
antiphospholipid antibodies | 3 |
interactive consultation | 3 |
response element | 3 |
monoclonal antibody | 3 |
bacterial infection | 3 |
person consultation | 3 |
associated microvascular | 3 |
clinical conditions | 3 |
scientific evidence | 3 |
findings associated | 3 |
viral replication | 3 |
northern italy | 3 |
potentially life | 3 |
two different | 3 |
inflammatory responses | 3 |
multiple drug | 3 |
till now | 3 |
lung injury | 3 |
daily practice | 3 |
symmetrical drug | 3 |
repeat length | 3 |
unusual case | 3 |
bullous disease | 3 |
year survival | 3 |
biologic therapies | 3 |
young patients | 3 |
since december | 3 |
potential role | 3 |
last months | 2 |
modifying drugs | 2 |
vesiculobullous lesions | 2 |
sequential occurrence | 2 |
dermatology department | 2 |
infection include | 2 |
best possible | 2 |
mild fever | 2 |
general symptoms | 2 |
patient contracted | 2 |
infectious agents | 2 |
suggesting dress | 2 |
recent article | 2 |
consistent number | 2 |
tqz bkdo | 2 |
immune changes | 2 |
new disease | 2 |
potential pathogenesis | 2 |
french ministry | 2 |
rapidly become | 2 |
continue long | 2 |
measures led | 2 |
per i | 2 |
vacuolar interface | 2 |
requiring close | 2 |
invasive cutaneous | 2 |
patients developed | 2 |
male patients | 2 |
develop covid | 2 |
unknown aetiology | 2 |
clinical picture | 2 |
epidemiological criteria | 2 |
marked reduction | 2 |
angiotensin ii | 2 |
early spring | 2 |
sore throat | 2 |
skin disorders | 2 |
organ failure | 2 |
lesions surrounded | 2 |
breslow thickness | 2 |
cutaneous covid | 2 |
vasculitic eruptions | 2 |
people requiring | 2 |
virus infections | 2 |
therefore suggested | 2 |
multicenter case | 2 |
hospital treatment | 2 |
unjustified accesses | 2 |
hives ranging | 2 |
vcfu ij | 2 |
au ml | 2 |
observed two | 2 |
people around | 2 |
igg antibodies | 2 |
another differential | 2 |
nationwide lockdown | 2 |
related intertriginous | 2 |
dermatological practice | 2 |
high morbidity | 2 |
inflammatory bowel | 2 |
cutaneous vessels | 2 |
methylprednisolone mg | 2 |
muting early | 2 |
sanitary emergency | 2 |
consequences may | 2 |
superficial dermis | 2 |
recognised thereafter | 2 |
public centers | 2 |
sessualmente trasmesse | 2 |
hospital access | 2 |
isolation measures | 2 |
exponential contagion | 2 |
still unclear | 2 |
priority list | 2 |
postural habits | 2 |
first days | 2 |
symmetric lr | 2 |
pkx zu | 2 |
include eruptions | 2 |
experienced specialists | 2 |
mediated reaction | 2 |
released incentives | 2 |
wet extremities | 2 |
health concern | 2 |
forged theexponential | 2 |
patients also | 2 |
medical masks | 2 |
widespread urticaria | 2 |
significantly lower | 2 |
authors conclude | 2 |
conventional respiratory | 2 |
first time | 2 |
severe respiratory | 2 |
transmitted diseases | 2 |
people every | 2 |
laboratory data | 2 |
may represents | 2 |
clinicopathological correlation | 2 |
potentially show | 2 |
perivascular infiltrate | 2 |
true outbreak | 2 |
health problems | 2 |
causing purpuric | 2 |
worldwide medical | 2 |
wears face | 2 |
pros cons | 2 |
disease cutaneous | 2 |
significant reduction | 2 |
underlying conditions | 2 |
antiviral immunity | 2 |
total number | 2 |
hemorrhagic vasculitis | 2 |
regular medication | 2 |
italy date | 2 |
reserved dear | 2 |
dermatological diseases | 2 |
otherwise known | 2 |
subacute phases | 2 |
post viral | 2 |
poorly described | 2 |
cell count | 2 |
children pityriasis | 2 |
million patients | 2 |
intravenous ceftriaxone | 2 |
cytoplasmic antibody | 2 |
societal changes | 2 |
also inducing | 2 |
also known | 2 |
immunohistochemical evaluation | 2 |
including clinical | 2 |
eruptions induced | 2 |
aq hb | 2 |
incorrect postural | 2 |
described within | 2 |
messaging group | 2 |
national institute | 2 |
prolonged sessions | 2 |
wet indoor | 2 |
enzyme implicated | 2 |
observations led | 2 |
doxycycline tetracycline | 2 |
major cluster | 2 |
storm induced | 2 |
health issue | 2 |
many countries | 2 |
new management | 2 |
workers due | 2 |
onset neonatal | 2 |
surpassing china | 2 |
hospitalized men | 2 |
young patient | 2 |
immune responses | 2 |
independent prognostic | 2 |
dysregulated host | 2 |
data transmission | 2 |
morbilliform rash | 2 |
coronavirus covid | 2 |
enormous health | 2 |
worst pandemic | 2 |
among hospitalized | 2 |
qreg emx | 2 |
dermatology may | 2 |
injury caused | 2 |
viral pandemic | 2 |
mainly teenagers | 2 |
covid era | 2 |
may cause | 2 |
western country | 2 |
fs dxg | 2 |
transformation tests | 2 |
day history | 2 |
age ranged | 2 |
patients already | 2 |
vascular injury | 2 |
explosive spread | 2 |
outside cohabitants | 2 |
plaque psoriasis | 2 |
tertiary care | 2 |
symptoms may | 2 |
vascular changes | 2 |
common symptoms | 2 |
ujnks ox | 2 |
systemic therapies | 2 |
punch biopsy | 2 |
quality standards | 2 |
vascular lesions | 2 |
ebv reactivation | 2 |
letter reports | 2 |
also display | 2 |
growing number | 2 |
although many | 2 |
tests revealed | 2 |
icu inpatient | 2 |
nosocomial infection | 2 |
drug hypersensitivity | 2 |
th march | 2 |
blood cells | 2 |
del marmol | 2 |
mainly characterized | 2 |
drug involvement | 2 |
showing nuclear | 2 |
genus betacoronavirus | 2 |
infection presenting | 2 |
changes due | 2 |
elderly patients | 2 |
vasculitic purpura | 2 |
may potentially | 2 |
new virus | 2 |
histological findings | 2 |
initial biochemical | 2 |
surveillance system | 2 |
median incubation | 2 |
health system | 2 |
major societal | 2 |
damage caused | 2 |
small vessels | 2 |
new pathogen | 2 |
published articles | 2 |
skin eruptions | 2 |
vasculitis presenting | 2 |
related immunotherapy | 2 |
ycc i | 2 |
low platelet | 2 |
none showed | 2 |
clinical signs | 2 |
general prevention | 2 |
many patients | 2 |
syndrome associated | 2 |
brain oligodendroglioma | 2 |
rna performed | 2 |
three weeks | 2 |
display skin | 2 |
theexponential use | 2 |
alcohol solution | 2 |
various kinds | 2 |
potentially implicated | 2 |
male covid | 2 |
fast become | 2 |
rashes associated | 2 |
currently dealing | 2 |
blood test | 2 |
dedicated centers | 2 |
randomly selected | 2 |
well lead | 2 |
improve access | 2 |
epidermolysis bullosa | 2 |
common pathogenetic | 2 |
inflammatory cytokine | 2 |
cancer treatment | 2 |
enterovirus rna | 2 |
clinical patterns | 2 |
forward teledermatology | 2 |
prostate cancer | 2 |
funding sources | 2 |
serious infections | 2 |
frequent hand | 2 |
term surveillance | 2 |
pcr testing | 2 |
really urticaria | 2 |
fz bj | 2 |
spanish pharmacovigilance | 2 |
responses triggered | 2 |
affected patients | 2 |
currently spreading | 2 |
including one | 2 |
university hospital | 2 |
joint committee | 2 |
french dermatologists | 2 |
true emergencies | 2 |
medical staff | 2 |
nationwide population | 2 |
i pazienti | 2 |
host inflammatory | 2 |
simplex reactivation | 2 |
kg day | 2 |
major chronic | 2 |
telephone consultation | 2 |
manifestations associated | 2 |
include erythematous | 2 |
previous reports | 2 |
moderate disease | 2 |
articles detailed | 2 |
symmetric livedo | 2 |
histological examination | 2 |
medical reasons | 2 |
bologna belongs | 2 |
cancer triage | 2 |
saturation point | 2 |
mask induced | 2 |
culprit drug | 2 |
tests showed | 2 |
widespread viral | 2 |
severe manifestations | 2 |
affect millions | 2 |
delays due | 2 |
acute myocardial | 2 |
clinical choices | 2 |
guarantee high | 2 |
china cutaneous | 2 |
year worldwide | 2 |
etanercept provides | 2 |
dermatology outpatient | 2 |
biologic therapy | 2 |
jinyintan hospital | 2 |
dermatologic manifestations | 2 |
emilia romagna | 2 |
certain health | 2 |
wide variety | 2 |
yet little | 2 |
pandemic resolves | 2 |
jaad case | 2 |
trained eyes | 2 |
organ involvement | 2 |
international concern | 2 |
longitudinal study | 2 |
potentially severe | 2 |
reactive genital | 2 |
passed emergency | 2 |
disease associated | 2 |
intense immunosuppressive | 2 |
personal protection | 2 |
interest dr | 2 |
whitish halo | 2 |
pandemic forged | 2 |
influenza infection | 2 |
associated cutaneous | 2 |
higher incidence | 2 |
telemedicine implementation | 2 |
hemorrhagic bullous | 2 |
lifestyle changes | 2 |
erythrocytes extravasation | 2 |
catastrophic days | 2 |
symptoms plus | 2 |
critical patients | 2 |
certain degree | 2 |
recent review | 2 |
maintaining hospital | 2 |
worst event | 2 |
ct scan | 2 |
also described | 2 |
psoriasis patients | 2 |
normal limits | 2 |
reports new | 2 |
older age | 2 |
previous report | 2 |
risk factor | 2 |
predicting fatal | 2 |
research progress | 2 |
subsequent therapeutic | 2 |
first manifestations | 2 |
national field | 2 |
practice date | 2 |
organized nationwide | 2 |
common sense | 2 |
exact test | 2 |
reserved classification | 2 |
gonorrhoeae infections | 2 |
predictive value | 2 |
direct damage | 2 |
immunomodulatory agents | 2 |
like manifestations | 2 |
exanthem associated | 2 |
new cutaneous | 2 |
population containment | 2 |
disease compared | 2 |
northern italian | 2 |
pulmonary embolism | 2 |
include fever | 2 |
within normal | 2 |
generalised pruritic | 2 |
provides protection | 2 |
preliminary data | 2 |
related cutaneous | 2 |
first western | 2 |
pandemic experienced | 2 |
mg bid | 2 |
airborne spread | 2 |
risk contact | 2 |
asymptomatic patients | 2 |
chicken pox | 2 |
polycyclic erythema | 2 |
early viral | 2 |
dermatologic findings | 2 |
controlling nosocomial | 2 |
cell carcinoma | 2 |
case described | 2 |
fatal cytomegalovirus | 2 |
specific mucosal | 2 |
risk might | 2 |
chest pain | 2 |
bullous eruption | 2 |
highly contagious | 2 |
melanoma thickness | 2 |
managing covid | 2 |
starting azithromycin | 2 |
treg function | 2 |
may originate | 2 |
case study | 2 |
chronic urticaria | 2 |
created concern | 2 |
drug withdrawal | 2 |
white blood | 2 |
elderly man | 2 |
societal impacts | 2 |
atypical lymphocytes | 2 |
viral shedding | 2 |
triggering factors | 2 |
pathological study | 2 |
cancer progression | 2 |
viral exanthema | 2 |
ideal management | 2 |
additional data | 2 |
patient date | 2 |
reports concerning | 2 |
although contact | 2 |
patients accessed | 2 |
year old | 2 |
revealed bilateral | 2 |
delayed immune | 2 |
american academy | 2 |
early ifn | 2 |
outbreak begun | 2 |
arginine methyltransferase | 2 |
chronic obstructive | 2 |
health released | 2 |
first published | 2 |
acral manifestations | 2 |
generalized maculopapular | 2 |
blood samples | 2 |
late winter | 2 |
cov pandemia | 2 |
experiencing retroauricaular | 2 |
immunosuppressive approaches | 2 |
diagnostic delays | 2 |
ie iklr | 2 |
aged match | 2 |
preventing widespread | 2 |
among experts | 2 |
distancing measures | 2 |
less frequent | 2 |
melanoma staging | 2 |
months ago | 2 |
infezione da | 2 |
abd patients | 2 |
oe i | 2 |
approximately patients | 2 |
patients observed | 2 |
psoriasis health | 2 |
match population | 2 |
including dermatologic | 2 |
diagnostic question | 2 |
management require | 2 |
previous years | 2 |
maculopapular rash | 2 |
clinical examination | 2 |
skin biopsies | 2 |
atrial fibrillation | 2 |
text messaging | 2 |
several countries | 2 |
positive rt | 2 |
prognostic factor | 2 |
contacts outside | 2 |
acral areas | 2 |
immune dysregulation | 2 |
coronavirus infections | 2 |
underlying diseases | 2 |
swab negativity | 2 |
assay skin | 2 |
median duration | 2 |
age years | 2 |
pathogenetic mechanisms | 2 |
mild form | 2 |
human herpesvirus | 2 |
allergic contact | 2 |
published cases | 2 |
developed dihs | 2 |
new dermatologic | 2 |
effective immune | 2 |
health systems | 2 |
epidemiological features | 2 |
get severe | 2 |
dermatologic consultations | 2 |
human cells | 2 |
timely manner | 2 |
pharmacovigilance system | 2 |
management modalities | 2 |
tumor thickness | 2 |
service access | 2 |
novel covid | 2 |
requiring intensive | 2 |
young outpatients | 2 |
add i | 2 |
increase risk | 2 |
cutis marmorata | 2 |
acral ischemia | 2 |
last month | 2 |
infectious disease | 2 |
mean age | 2 |
controlling virus | 2 |
every year | 2 |
walked barefoot | 2 |
utz ulcers | 2 |
symptoms including | 2 |
pulmonary symptoms | 2 |
dermatologic unit | 2 |
injury may | 2 |
four continents | 2 |
protein arginine | 2 |
huge impact | 2 |
unprecedented case | 2 |
van damme | 2 |
spread quickly | 2 |
may continue | 2 |
social contacts | 2 |
various types | 2 |
eosinophils within | 2 |
less severe | 2 |
italian regions | 2 |
isolated sudden | 2 |
different indications | 2 |
respiratory failure | 2 |
individual basis | 2 |
health personnel | 2 |
observed skin | 2 |
rectal swabs | 2 |
presentation pattern | 2 |
four cases | 2 |
cases cutaneous | 2 |
positive igm | 2 |
without treatment | 2 |
improve covid | 2 |
tests will | 2 |
indirect contact | 2 |
patient flow | 2 |
care professionals | 2 |
french union | 2 |
exaggerated inflammatory | 2 |
pandemic viral | 2 |
dapsone sulfapyridine | 2 |
induced vasculitis | 2 |
new type | 2 |
new clinical | 2 |
retrospective cohort | 2 |
directed therapies | 2 |
petechial rash | 2 |
viral transmission | 2 |
disease propagation | 2 |
neonatal sepsis | 2 |
sexual orientation | 2 |
infection resolution | 2 |
considering urticarial | 2 |
lesion biopsy | 2 |
cag score | 2 |
skin involvement | 2 |
progressively improved | 2 |
surveillance strategy | 2 |
decree law | 2 |
severe plaque | 2 |
minister announced | 2 |
showed bilateral | 2 |
inducing microangiopathic | 2 |
percentage may | 2 |
systemic treatments | 2 |
leg ulcers | 2 |
cellular receptor | 2 |
reported occurrence | 2 |
inflammatory parameters | 2 |
known promoter | 2 |
without general | 2 |
aggressive interstitial | 2 |
men infected | 2 |
sentinel surveillance | 2 |
symptoms severity | 2 |
drug intake | 2 |
great attention | 2 |
well reported | 2 |
social isolation | 2 |
severe form | 2 |
androgen modifying | 2 |
drugs prescribed | 2 |
emergency management | 2 |
three patients | 2 |
systemic treatment | 2 |
arthritis treated | 2 |
cytomegalovirus disease | 2 |
scoring system | 2 |
nine days | 2 |
health procedures | 2 |
medical doctors | 2 |
examination revealed | 2 |
patients without | 2 |
therapeutic repercussions | 2 |
modern times | 2 |
medical community | 2 |
currently living | 2 |
patient tested | 2 |
possible among | 2 |
high fever | 2 |
plus general | 2 |
pandemic may | 2 |
article entitled | 2 |
pathogenetic mechanism | 2 |
positive result | 2 |
pulmonary infection | 2 |
undergoing immunosuppressive | 2 |
relatively unexplored | 2 |
necrotic outcome | 2 |
tissue damage | 2 |
first focus | 2 |
acute subacute | 2 |
also observed | 2 |
several months | 2 |
immunosuppressed patients | 2 |
nodosum like | 2 |
therefore reached | 2 |
lm rr | 2 |
retroauricaular dermatitis | 2 |
induced dermatitis | 2 |
whose management | 2 |
acute lung | 2 |
china several | 2 |
obstructive pulmonary | 2 |
different issues | 2 |
prospective longitudinal | 2 |
blood flow | 2 |
manifestations seem | 2 |
complete blood | 2 |
medicines agency | 2 |
experience may | 2 |
facilitate live | 2 |
future major | 2 |
rash consisting | 2 |
curable sexually | 2 |
without symptoms | 2 |
covid across | 2 |
medications administered | 2 |
operating rooms | 2 |
pytiriasis rosea | 2 |
swab positive | 2 |
across italy | 2 |
strictly forbidding | 2 |
emergency laws | 2 |
circinate erythema | 2 |
general practitioners | 2 |
mg kg | 2 |
similar aged | 2 |
countries around | 2 |
health professionals | 2 |
ng ml | 2 |
possibly due | 2 |
quantitative reverse | 2 |
intravenous corticosteroids | 2 |
europe became | 2 |
stds service | 2 |
biologic agents | 2 |
directly related | 2 |
acute reactive | 2 |
onset anosmia | 2 |
last weeks | 2 |
social networks | 2 |
may predispose | 2 |
acute infections | 2 |
healthcare professionals | 2 |
recently reported | 2 |
reducing mortality | 2 |
severe psoriasis | 2 |
current evidence | 2 |
therapeutic strategy | 2 |
take special | 2 |
clinicopathologic correlation | 2 |
several associated | 2 |
two published | 2 |
pruritic hives | 2 |
microangiopathic changes | 2 |
coronavirus outbreak | 2 |
symptoms appear | 2 |
travelers returning | 2 |
contribution viral | 2 |
causative agent | 2 |
old woman | 2 |
perspective covid | 2 |
hemorrhagic edema | 2 |
skin necrosis | 2 |
skin barrier | 2 |
psoriasis patient | 2 |
papillary dermal | 2 |
inpatient beds | 2 |
primary care | 2 |
uztk pc | 2 |
european countries | 2 |
cases related | 2 |
changes observed | 2 |
patients covid | 2 |
chest radiograph | 2 |
ischemia vascular | 2 |
irritant dermatitis | 2 |
infections among | 2 |
outpatients visited | 2 |
developed skin | 2 |
dress days | 2 |
italian medicines | 2 |
localized invasive | 2 |
general malaise | 2 |
true emergency | 2 |
challenging particularly | 2 |
infection date | 2 |
targets specifically | 2 |
stimulating drugs | 2 |
presumably specific | 2 |
covid testing | 2 |
authors thank | 2 |
cytokine tumor | 2 |
causing enormous | 2 |
live interactive | 2 |
biochemical tests | 2 |
previous exposure | 2 |
th percentile | 2 |
acute hemorrhagic | 2 |
hemorrhagic dermatosis | 2 |
blood tests | 2 |
require experienced | 2 |
produce diverse | 2 |
via indirect | 2 |
pox like | 2 |
body temperature | 2 |
coagulation parameters | 2 |
different skin | 2 |
american joint | 2 |
rapid spread | 2 |
covid health | 2 |
inflammatory disorder | 2 |
immune system | 2 |
possible balance | 2 |
radiotherapy departments | 2 |
like symptoms | 2 |
countries organized | 2 |
three times | 2 |
present outbreak | 2 |
including spain | 2 |
often without | 2 |
increased disease | 2 |
patients experiencing | 2 |
covid infection | 2 |
frequent covid | 2 |
zoster virus | 2 |
eosinophilic granulomatosis | 2 |
lecco hospital | 2 |
per se | 2 |
medical education | 2 |
spreading worldwide | 2 |
temporal correlation | 2 |
low numbers | 2 |
seven patients | 2 |
cumulative incidence | 2 |
predispose male | 2 |
regional health | 2 |
italian sentinel | 2 |
possible association | 2 |
androgen mediated | 2 |
benign acral | 2 |
four psoriatic | 2 |
aetiologic agent | 2 |
among travelers | 2 |
including children | 2 |
histopathologic findings | 2 |
scarce evidence | 2 |
wuhan jinyintan | 2 |
without additional | 2 |
growth model | 2 |
respiratory manifestations | 2 |
simplex virus | 2 |
details key | 2 |
discrete symptoms | 2 |
national health | 2 |
transmit via | 2 |
available icu | 2 |
outpatient service | 2 |
first presented | 2 |
may require | 2 |
may well | 2 |
antiviral drugs | 2 |
perspective clinical | 2 |
clinical practice | 2 |
gene may | 2 |
end organ | 2 |
damage might | 2 |
descriptive study | 2 |
usual clinical | 2 |
specific covid | 2 |
bullosa acquisita | 2 |
trigger factors | 2 |
patients referred | 2 |
appropriate clinical | 2 |
major health | 2 |
estimated effect | 2 |
dermatitis herpetiformis | 2 |
respiratory tract | 2 |